Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

  (2 citations)     
Datasheet / CoA / SDS
Product Details
Citations (2)
Supplemental Products
  • Purity
    >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Endotoxin Level
    <0.01 EU per 1 μg of the protein by the LAL method.
  • Activity
    Measured by its ability to inhibit Type-I IFN-mediated anti-viral activity. The ED50 for this effect, as measured by inhibition of Recombinant Human IFN‑ beta (Catalog # 8499-IF) , is 0.1-0.6 μg/mL
  • Source
    Mouse myeloma cell line, NS0-derived human IFN-alpha/beta R2 protein
    Human IFN-alpha / beta R2
    Accession # P48551
    IEGRMD Human IgG1
    N-terminus C-terminus
  • Accession #
  • N-terminal Sequence
  • Structure / Form
    Disulfide-linked homodimer
  • Predicted Molecular Mass
    51.3 kDa (monomer)
    71-76 kDa, reducing conditions
Product Datasheets

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Data Image
Recombinant Human IFN-alpha/beta R2 Fc Chimera (Catalog #4015-AB) inhibits the anti-viral activity ofRecombinant Human IFN-beta (Catalog # 8499-IF). The ED50 for thiseffect is 0.1-0.6 μg/mL.
Background: IFN-alpha/beta R2

IFN-alpha / beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). IFN-alpha / beta R2, in association with IFN-alpha / beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta. IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (3, 4). Mature human IFN-alpha / beta R2 consists of a 217 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 251 aa cytoplasmic domain. Alternate splicing generates a secreted isoform that corresponds to the ECD and a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (5, 6). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (7 - 9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta, while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12). Within the ECD, human IFN-alpha / beta R2 shares 63%, 60%, and 48% aa sequence identity with bovine, mouse, and ovine IFN-alpha / beta R2, respectively.

  • References:
    1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
    2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
    3. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
    4. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
    5. Lutfalla, G. et al. (1995) EMBO J. 14:5100.
    6. Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
    7. Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
    8. Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
    9. Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
    10. Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
    11. McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
    12. Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.
  • Long Name:
    Interferon alpha/beta Receptor 2
  • Entrez Gene IDs:
    3455 (Human); 15976 (Mouse)
  • Alternate Names:
    beta receptor10; human interferon alpha; human interferon alpha/beta receptor; IFNABR; IFN-alpha binding protein; IFN-alpha/beta R2; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFNAR2; IFN-aR2; IFNARB; IFNbR2; IFN-bR2; IFN-R; IFN-R-2; interferon (alpha, beta and omega) receptor 2; Interferon alpha binding protein; interferon alpha/beta receptor 2; interferon-alpha/beta receptor beta chain; Type I interferon receptor 2
Related Research Areas

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Sample Type
  1. Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation
    Authors: S Soonthornv, A Rodriguez-, Y Zhou, F Galvez, NJ Huffmaster, S Tripathi, VR Balasubram, A Inoue, E de Castro, H Moulton, DA Stein, MT Sánchez-Ap, PD De Jesus, Q Nguyen, R König, NJ Krogan, A García-Sas, SM Yoh, SK Chanda
    Nat Microbiol, 2017;2(0):17022.
    Species: Human
    Sample Type: Whole Cells
    Application: Bioassay
  2. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo.
    Authors: Li M, Rao C, Pei D, Wang L, Li Y, Gao K, Wang M, Wang J
    Cancer Cell Int, 2014;14(1):8.
    Species: N/A
    Sample Type: Chip
    Application: Surface Plasmon Resonance


No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Primary Antibodies
Description Application Cat# Citations Images  

Human IgG1 Antibody

WB , ELISA MAB9894  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Recombinant Proteins
Description Application Cat# Citations Images  

Recombinant Human IgG1 Fc Protein, CF

BA 110-HG 70
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Reconstitution Buffers
Description Application Cat# Citations Images  

Reconstitution Buffer 1 (PBS)

View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Have you used Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Us to Order


Customer Information

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

R&D Systems Guarantee